An early decision of transjugular intrahepatic portosystemic shunt may be considered for non-malignant and non-cirrhotic portal vein thrombosis with ascites: a concise review of the theoretical possibility and practical difficulty
More details
Hide details
Submission date: 2014-12-10
Acceptance date: 2015-01-16
Online publication date: 2016-10-24
Publication date: 2016-10-20
Arch Med Sci 2016;12(6):1381–1383
Aims: A systematic review of the literature was conducted to explore the association of portal vein thrombosis (PVT) with the risk of bleeding in liver cirrhosis. Methods: PubMed, EMBASE, and Cochrane library databases were searched for all relevant papers which compared the prevalence of bleeding at baseline and/or incidence of bleeding during follow-up between cirrhotic patients with and without PVT. Results: Fourteen papers were eligible for this study. The heterogeneity among studies was marked with regards to the treatment modalities, sources of bleeding, lengths of follow-up, and ways of data expression. But most of their findings were homozygous and suggested that the cirrhotic patients with PVT were more likely to have previous histories of variceal bleeding at their admission and to develop de novo bleeding and rebleeding during the short- and long-term follow-up. However, as for the cirrhotic patients with gastric variceal bleeding treated with medical/endoscopic therapy, the association of PVT with the risk of rebleeding remained controversial in 2 studies. In addition, as for the cirrhotic patients undergoing transjugular intrahepatic portosystemic shunts for the management of variceal bleeding, a pre-existing PVT was not associated with the risk of rebleeding. Conclusions: Based on the systematic review of the literature, there was a positive association between the presence of PVT and risk of bleeding in liver cirrhosis in most of clinical conditions. This might suggest the necessity of recanalizing the thrombosed portal vein in liver cirrhosis earlier.